Home2019-05-06T17:26:12+00:00
Loading...

Spotlight

Twitter feed

#Pembrolizumab Found to Be Safe, Effective as Second-Line Therapy for Advanced Esophageal Cancer: #ASCOdailynews #ASCO19 #esocsm #cancerresearch

Pembrolizumab Found to Be Safe, Effective as Second-Line Therapy for Advanced Esophageal Cancer

bit.ly

#Rivaroxaban Reduces VTE in Ambulatory Patients With Pancreatic Cancer: #ASCOdailynews #pancsm #pancreaticcancer

Rivaroxaban Reduces VTE in Ambulatory Patients With Pancreatic Cancer

bit.ly

Abstract submission deadline is May 31 for the @CR_UK-AACR Joint Conference: Engineering and Physical Sciences in Oncology. taking place in London, Oct. 15-17. Explore how emerging technologies and novel approaches can unlock new thinking in your field: https://t.co/bkmCyG2tAS

Nominations are open for the AACR Scientific Achievement Awards, which recognizes scientific excellence in Cancer Research. For more information including criteria and deadlines, visit https://t.co/7tFlDnVA2p

RT @CR_AACR: @UCLA @UCLAFSPH and @UHCancerCenter authors consider #Breastcancer Risk and #Insulin Resistance: Post Genome-Wide Gene–Environment Interaction Study Using a Random Survival Forest. https://t.co/N2lyk3ehaY

Thank you @senatemajldr & @timkaine for introducing the Tobacco-Free Youth Act, raising the #tobacco purchasing age from 18 to 21. We joined several stakeholders endorsing this bill #ASCOinAction

ASCO Supports the Tobacco-Free Youth Act

”ASCO strongly supports this strong, bipartisan bill that would raise the federal age for purchasing tobacco products, electronic cigarettes, an...

fal.cn

Register for #OncPractice19, a conference focused on the business of cancer care, taking place Sept. 5 in San Diego https://t.co/ALdSM7Uo2m

RT @CAPR_AACR: Now available online- check out the must read article collection featuring the Journal's most highly- cited and viewed items from last year! https://t.co/wpU88i8L5Q

Recent publications

Ultra-deep next-generation sequencing of plasma cell-free DNA in patients with advanced lung cancers: results from the Actionable Genome Consortium. Ann. Oncol.

Olaparib and α-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial. Lancet Oncol.

All publications

Announcements

Please check back soon for new announcements

Research

Target identification and validation image
Target identification and validation
Photo of scientist carefully adding fluid to multiple test tubes
Drug discovery and development
Photo of Belfer Center researcher working at computer
Clinical science and correlatives

Strategic alliances

Graphic showing circular relationship of research, medicine, and industry

Our strategic alliances drive research innovations and lead to improved therapies to benefit cancer patients

Collaborate with us

Our people

Background image is a collage of photos showing Belfer Center members

Donor highlight

Robert and Renée Belfer’s transformative cumulative Dana-Farber investment of more than $25 million launched the Robert A. and Renée E. Belfer Center for Applied Cancer Science. Their generosity enabled the Belfer Center to integrate its scientific teams, produce innovative cancer models, partner with industry leaders, and accelerate the development of revolutionary therapies to treat cancer. We are grateful for their vision and incredible support.

Photo of donors, Mr. and Mrs Belfer